Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
CTR20262751 SGT003 (Sungen) Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262751 clinical trial report covering SGT003 (Sungen), Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07712562 Dibotatug Anemia, Aplastic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07712562 clinical trial report covering Dibotatug, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07711223 Asuptegravir/Emtricitabine/Tenofovir Alafenamide HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07711223 clinical trial report covering Asuptegravir/Emtricitabine/Tenofovir Alafenamide, Phase 1/2, endpoints, sponsor, geography, readout timing and d
Latest Hotspot
8 min read
NCT07714395 Elraglusib Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07714395 clinical trial report covering Elraglusib, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262659 Bevacizumab biosimilar(Qilu Pharmaceutical Co., Ltd.) Colorectal Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262659 clinical trial report covering Bevacizumab biosimilar(Qilu Pharmaceutical Co., Ltd.), Phase 1/2, endpoints, sponsor, geography, readout timing
Latest Hotspot
8 min read
CTR20262602 BH-015 Muscle Invasive Bladder Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262602 clinical trial report covering BH-015, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07717905 BBT-001(Bambusa Therapeutics) Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07717905 clinical trial report covering BBT-001(Bambusa Therapeutics), Phase 1/2, endpoints, sponsor, geography, readout timing and development white sp
Latest Hotspot
8 min read
NCT07718243 Nivolumab Melanoma, Cutaneous Malignant Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07718243 clinical trial report covering Nivolumab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07718581 HMPL-A830 Solid tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07718581 clinical trial report covering HMPL-A830, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07719348 Posaconazole Myeloid Tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07719348 clinical trial report covering Posaconazole, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07723482 ML-016 Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07723482 clinical trial report covering ML-016, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07724873 Withania somnifera Extract Hematologic Neoplasms Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07724873 clinical trial report covering Withania somnifera Extract, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space